Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Asterias Biotherapeutics

- PMLiVE

Boehringer files nintedanib for lung cancer in Europe

Pharma company seeks approval for second oncology drug

- PMLiVE

Merck’s anti-PD1 drug promising in lung cancer

Positive results in phase Ib trial

- PMLiVE

ECC 2013: Nintedanib data boosts Boehringer’s oncology ambitions

Lung cancer drug shows extended overall survival in adenocarcinoma patients

- PMLiVE

Boehringer’s oncology unit scores first EU approval

Giotrif given green light for non-small cell lung cancer

National Institute for Health and Care Excellence NICE logo

NICE questions cost of medicines development

Says pharma should determine if R&D spending of £1bn+ per drug is really necessary

- PMLiVE

Boehringer readies first cancer drug Gilotrif for US launch

Will mark milestone for the pharma company's oncology research efforts

- PMLiVE

Lilly buoyant as lung cancer hope clears pivotal study

Necitumumab on course for regulatory submission in 2014

National Institute for Health and Care Excellence NICE logo

NICE recommends tests to detect lung cancer mutation

Offers guidance on what NHS can use to see what patients have the EGFR gene mutation

- PMLiVE

Boehringer breaks into oncology with FDA approval

Agency backs company's first cancer drug afatinib in lung cancer

- PMLiVE

UK relaunches lung cancer campaign

Follows success in previous awareness push

- PMLiVE

NICE knocks back Lilly’s Alimta in new setting

Institute not recommending Lilly’s lung cancer drug for new licence extension

- PMLiVE

ASCO: Boehringer’s nintedanib boosts survival in lung cancer subset

Trial date demonstrates benefit in NSCLC patients with adenocarcinomas

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links